Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 20 of 116

  1. Placebo

    Regeneron UK Limited

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  2. Placebo

    Sanofi Pasteur

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  3. Placebo

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Carcinoma

    phase 3 small molecule terminated

    1 trial

  4. Placebo

    Amgen

    Breast Cancer

    phase 3 small molecule terminated

    1 trial

  5. Placebo

    Eli Lilly and Company

    Hepatocellular Carcinoma

    phase 3 mab completed

    1 trial

  6. Placebo matching REGN7508, REGN7508

    Lacuna Pharma Pty Ltd

    Cancer-Associated Thrombosis (CAT).

    phase 3 small molecule active

    1 trial

  7. Placebo, CEMIPLIMAB

    Ningbo Cancer Hospital

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  8. Placebos

    Jian Li

    Advanced Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  9. Ponatinib

    Takeda

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

    phase 3 small molecule active

    1 trial

  10. Ponatinib 30 mg QD

    Takeda

    Chronic Phase Chronic Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial

  11. Ponatinib-3001

    Takeda

    Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  12. Prostavue

    Curium Romania S.R.L.

    Prostate cancer

    phase 3 small molecule active

    1 trial

  13. Puxitatug Samrotecan

    AstraZeneca

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  14. QL2107, PEMBROLIZUMAB

    Lacuna Pharma Pty Ltd

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  15. Quemliclustat

    Arcus Biosciences

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  16. R2810-ONC-16113

    Lacuna Pharma Pty Ltd

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. R2810-ONC-1624

    Lacuna Pharma Pty Ltd

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. R2810-ONC-1788

    Lacuna Pharma Pty Ltd

    Cutaneous Squamous Cell Carcinoma (CSCC)

    phase 3 small molecule active

    1 trial

  19. R3767-ONC-2011

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 3 small molecule active

    1 trial

  20. R3767-ONC-2235

    Lacuna Pharma Pty Ltd

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  21. RAMIRIS

    The George Institute

    advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctions, who failed prior line of palliative chemotherpay

    phase 3 small molecule active

    1 trial

  22. RAMUCIRUMAB, ERLOTINIB

    Eli Lilly Co.

    Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  23. REGN2810

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  24. REGN2810/ipi

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  25. REGN7508

    Regeneron UK Limited

    Cancer-Associated Thrombosis (CAT)

    phase 3 small molecule active

    1 trial

  26. REINFORCE

    Disc Medicine

    Metastatic hormone-sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  27. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Carcinoma, Squamous Cell of the Head and Neck

    phase 3 mab completed

    2 trials

  28. RLY-2608-102

    Relay Therapeutics

    PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  29. RMC-6236

    Revolution Medicines

    Pancreatic Cancer

    phase 3 small molecule active

    1 trial

  30. RMC-6236-301

    Revolution Medicines

    non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  31. RMC-6236-302

    Revolution Medicines

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  32. RO5541267

    Hoffmann-La Roche

    Cohort A: • Metastatic non-small cell lung carcinoma (mNSCLC) • Extensive-stage small-cell lung carcinoma (ES-SCLC) • Advanced or unresectable hepatocellular carcinoma (HCC) Cohort B: • Resected Stage IIB-IIIB (early-stage; per the UICC/AJCC staging system, 8th edition) non-small cell lung carcinoma (NSCLC)

    phase 3 small molecule active

    1 trial

  33. RT2019-13

    Disc Medicine

    Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases

    phase 3 small molecule active

    1 trial

  34. Radiotherapy

    International Peace Maternity and Child Health Hospital

    Cervix Cancer

    phase 3 other completed

    1 trial

  35. Raloxifene - Usual

    Lxo Ireland Designated Activity Company

    Breast Cancer

    phase 3 small molecule active

    1 trial

  36. Raludotatug Deruxtecan

    Merck Sharp and Dohme

    Gastrointestinal Cancers

    phase 3 small molecule active

    1 trial

  37. Ramucirumab

    Eli Lilly and Company

    Urothelial Carcinoma

    phase 3 small molecule completed

    1 trial

  38. Realgar-Indigo naturalis formula

    The First People's Hospital of Lianyungang

    Acute Promyelocytic Leukemia

    phase 3 small molecule active

    1 trial

  39. Regorafenib

    United Therapeutics Europe Ltd

    Gastro-Oesophageal Cancer

    phase 3 small molecule active

    1 trial

  40. Regorafenib (BAY73-4506)

    Bayer HealthCare AG

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  41. Relacorilant, 100 mg and 25 mg

    CORCEPT THERAPEUTICS INC

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule terminated

    1 trial

  42. Relugolix

    Myovant Sciences GmbH

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  43. Repotrectinib

    Bristol-Myers Squibb

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    1 trial

  44. Retifanlimab (INCMGA00012) for Squamous Carcinoma of the Anal Canal

    Incyte

    Squamous Carcinoma of the Anal Canal

    phase 3 small molecule active

    1 trial

  45. Revumenib

    United Therapeutics Europe Ltd

    Acute Myeloid Leukemia, Adult

    phase 3 small molecule active

    1 trial

  46. Revumenib

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 3 small molecule active

    1 trial

  47. Ribociclib

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  48. Ribociclib

    Novartis Pharmaceuticals

    Advanced, Metastatic Breast Cancer

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.